Autoimmune diseases represent a significant and complex global health burden, particularly among women, yet their underlying causes remain only partially understood. Affecting nearly every organ system, these conditions are driven by intricate interactions between genetic susceptibility, epigenetic modifications, and environmental triggers such as viral infections and toxins. With over 80 distinct autoimmune disorders identified—ranging from systemic to organ-specific—diagnosis and treatment continue to pose substantial clinical challenges. Despite progress in identifying autoantibodies and disease mechanisms, current therapies fall short of inducing long-term immune tolerance or preventing disease progression. This book offers a comprehensive exploration of the latest research into the molecular, genetic, and cellular underpinnings of autoimmune disease pathogenesis. It presents emerging therapeutic approaches grounded in advanced computational modeling, systems biology, and bioinformatics, as well as the design of novel bioactive compounds. A particular focus is placed on next-generation, nanoparticle-based drug delivery systems that promise to transform the treatment landscape by enhancing targeting specificity and minimizing systemic side effects. With in-depth coverage of Rheumatoid Arthritis (RA), Type 1 Diabetes (T1D), and Multiple Sclerosis (MS), this volume serves as a critical resource for specialists, researchers, and clinicians seeking to deepen their understanding of autoimmune disease mechanisms and therapeutic innovation. Through interdisciplinary insights and a forward-looking perspective, the book aims to accelerate the development of precision treatments that can significantly improve patient outcomes and quality of life.
